A three‐dimensional scar assessment tool for keloid scars: Volume, erythema and melanin quantified. Issue 6 (11th May 2021)

• Record Type: Journal Article
• Authors: Ruccia, Francesca; Zoccali, Giovanni; Cooper, Lilli; Rosten, Claire; Nduka, Charles
• Is Part Of: Skin research and technology. Volume 27:Issue 6(2021)
• Page Start: 1007
• Page End: 1016
• Publication Date: 2021-05-11
• Subjects: 3D imaging -- keloid -- scar assessment -- scarring -- steroid; Skin -- Research -- Periodicals; Skin -- Diseases -- Periodicals; Skin -- Physiology -- Periodicals; 616.5
• DOI: 10.1111/srt.13050
• Languages: English
• ISSNs: 0909-752X

Abstract

Abstract: Background: There is no non‐invasive objective assessment tool to measure keloid scar characteristics over time. This study aimed to ascertain the ability of the Antera 3D ® camera to detect differences in keloid features pre‐ and post‐steroid injection. In order to identify whether those variation could be considered as treatment response predicting factors. Methods: Enrolled patients received three intra‐lesional steroid injections at four‐weekly intervals. Images were taken with the Antera 3D camera 12 and 24 weeks after treatment. Keloids' colour, volume, and area as well as haemoglobin and melanin average levels and variation have been analysed pre‐ and post‐steroid injection. t Tests and relative risk have been used to analyse the significance and association strength of our finding. Results: Forty patients have been enrolled in the study. Significant changes as been recorded in keloids' volume and colour after steroid injection ( P < 0.05). 53% have recorded a Hb reduction showing no recurrence of pathology, patient who had increase in Hb showed an early recurrence. Melanin variation was significant after steroid injection ( P < 0.05) but no correlation has been found with treatment response. Conclusions: The Antera 3D camera is able to detect differences in the investigated keloid's features helping in two ways: by providing an objective, longitudinal method to monitor and document changes in scar morphology, and through monitoring haemoglobin change, which strongly correlates to both response to treatment and likelihood of recurrence. Allowing clinicians to identify which patients will respond early, in order to change treatment if necessary, limiting morbidity and costs.